Australian ovarian cancer survival up, but "early detection still key need"
This article was originally published in Clinica
The development of an effective early detection test remains the top priority for future research into ovarian cancer, Australian experts have said, following yesterday's publication of a report appraising the latest incidence and care outcomes data.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.